IN8bio (INAB) Stock News, Mar-Oct 2025

IN8bio (Nasdaq: INAB) reported significant clinical progress and financial results for Q2 2025. The company achieved a remarkable milestone in its INB-200 glioblastoma trial, with one patient surpassing four years without progression. Clinical data presented at ASCO 2025 showed patients receiving multiple doses achieved median progression-free survival of 16.1 months, more than double the standard-of-care outcome.

The company received recognition for its DeltEx™ manufacturing platform and presented promising preclinical data for INB-619, a gamma-delta T cell engager showing potential in lupus treatment. Financial results showed R&D expenses of $2.5M and G&A expenses of $2.7M, with a cash position of $13.2M extending runway into June 2026.

IN8bio announced a significant milestone in their Phase 1 trial of INB-200 gamma-delta T cell therapy for glioblastoma (GBM). A patient with grade 4, IDH-mutant glioma has achieved 4 years of remission and survival, maintaining good quality of life and returning to work. The Phase 1 trial data presented at ASCO 2025 showed INB-200's median progression-free survival (mPFS) of 16.1 months, more than double the 6.9 months typically seen with standard treatment. INB-200, the first genetically modified gamma-delta T cell therapy for GBM, has demonstrated a favorable safety profile and potential long-term benefits, marking a potential breakthrough in GBM treatment where standard care hasn't improved beyond 14-16 months overall survival in over 20 years.

IN8bio (NASDAQ: INAB) announced positive Phase 1 trial results for INB-200, their gamma-delta T cell therapy for newly diagnosed glioblastoma multiforme (GBM). The therapy demonstrated a median progression-free survival of 16.1 months in patients receiving multiple doses, more than double the 6.9 months typically observed with standard-of-care Stupp protocol. Four patients (40%) receiving repeated doses remain alive and progression-free for over two years, with three returning to work. The treatment showed favorable safety profile with no serious toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome. The company's Drug Resistant Immunotherapy (DRI) uses genetically modified gamma-delta T cells delivered directly into the brain in combination with standard maintenance chemotherapy. Preliminary Phase 2 trial data for INB-400 also shows promising results with mPFS at 10.8 months.

IN8bio (INAB) presented new preclinical data for INB-619, their gamma-delta T cell engager (TCE) therapy, at the ASGCT 2025 Annual Meeting. INB-619 demonstrated complete elimination of disease-causing B cells in blood samples from Systemic Lupus Erythematosus patients. The therapy successfully targets CD19+ B cells while expanding both Vδ1+ and Vδ2+ gamma-delta T cells.

Key advantages of INB-619 include its ability to deplete harmful IgG1 and IgM antibodies and achieve B cell elimination without triggering severe inflammatory responses like cytokine release syndrome (CRS). Unlike traditional CD3-based TCEs, the platform shows potential for safer and more precise immunotherapy for autoimmune diseases.

The company is exploring partnerships and additional indications where gamma-delta T cell biology and B cell targeting intersect.

IN8bio (NASDAQ: INAB) presented new data on its proprietary gamma-delta (γδ) T cell manufacturing program at ISCT 2025, receiving the Host Region Abstract Award. The company's DeltEx™ Allo manufacturing process demonstrated consistent production of potent cellular therapies for cancer treatment.

Key findings from the INB-100 study revealed: (1) Successful TCR reprogramming from αβ to γδ across all clinical batches, (2) High expression of cancer-killing and immune activation genes, and (3) Remarkable clinical outcomes with all 10 initial cohort patients remaining relapse-free for over a year, achieving a median overall survival of 23.3 months as of January 2024.

The company has automated its manufacturing program for rapid, reproducible production of cryopreserved cell therapy doses. The INB-100 trial is currently enrolling an expansion cohort at the recommended Phase 2 dose.

IN8bio (NASDAQ: INAB) reported significant progress in Q1 2025 with promising clinical results across its gamma-delta T cell therapy pipeline. The company's Phase 1 trial of INB-100 showed remarkable outcomes for Acute Myeloid Leukemia (AML) patients, with 100% remaining relapse-free after a median follow-up of 20.1 months. The therapy demonstrated impressive 1-year survival rates, with 90.9% progression-free survival and 100% overall survival. IN8bio also presented new data on their INB-600 T cell engager platform at AACR 2025, showing potential applications in both oncology and autoimmune diseases. Financially, the company raised $4.1 million through ATM sales and warrant exercises in Q1, ending the quarter with $11.9 million in cash. The company reported a net loss of $5.6 million ($0.07 per share), an improvement from the $8.6 million loss in the prior year period.

IN8bio (Nasdaq: INAB) announced upcoming presentations of new clinical and preclinical data from its gamma-delta T cell therapies platform at major scientific conferences. The company will showcase its research at four prestigious events: AACR 2025, ISCT 2025, ASGCT 2025, and ASCO 2025.

Key presentations include:

• A novel gamma-delta T cell engager platform for cancer immunotherapy at AACR
• Manufacturing processes and TCR repertoire analysis at ISCT
• INB-600 T cell engager platform and molecular signatures at ASGCT
• Phase 1 study results of INB-200 in glioblastoma patients at ASCO

CEO William Ho emphasized the scientific rigor and clinical potential of their platform, highlighting applications in both oncology and immune-mediated diseases. The presentations will focus on their INB-200/400 program in glioblastoma and novel T cell engager technologies.

IN8bio (NASDAQ: INAB) has unveiled promising preclinical data from its gamma-delta (γδ) T cell engager (TCE) platform at AACR 2025. The company's novel platform demonstrates significant γδ T cell expansion and activation without serious side effects like cytokine release syndrome.

The platform's lead molecules, INB-619 (targeting CD19) and INB-633 (targeting CD33), showed potent anti-cancer activity in leukemia models at low picomolar concentrations. Unlike traditional TCEs that activate all T cells through CD3, IN8bio's platform specifically activates γδ T cells, potentially offering a safer alternative with minimal inflammatory cytokine release.

Key findings show both molecules successfully expanded Vδ1+ and Vδ2+ cell subsets and demonstrated strong cancer-killing capabilities without triggering dangerous cytokine responses. The platform's off-the-shelf nature, requiring no genetic engineering, suggests potential for scalable immunotherapy development for both cancer and autoimmune diseases.

IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.

The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.

The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.